HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy
A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy
Sponsor: Fundação Faculdade de Medicina
Terminated
futility
Other terminated trials from Fundação Faculdade de Medicina
- Locally Advanced HER2-positive Breast Cancer · Phase PHASE2 · Sep 2012
- Locally Advanced HER2-negative Breast Cancer · Phase PHASE2 · Aug 2012
More terminations from Fundação Faculdade de Medicina
A PHASE2 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Fundação Faculdade de Medicina and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
▶ Show 4 earlier versions
-
Dec 2018 — Nov 2019 [monthly]
Suspended PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Suspended PHASE2
-
Mar 2017 — Jun 2018 [monthly]
Suspended PHASE2
-
Jan 2017 — Mar 2017 [monthly]
Suspended PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundação Faculdade de Medicina
- Instituto do Cancer do Estado de São Paulo
- Recepta Biopharma
For direct contact, visit the study record on ClinicalTrials.gov .